New inhaled asthma drug begins first human safety trial
NCT ID NCT07665892
First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 3 times
Summary
This early-stage trial tests a single inhaled dose of ASY202, a drug containing dihydroergotamine, in 40 adults with stable asthma. The study is randomized and placebo-controlled, meaning some participants get the drug and some get an inactive powder. The main goal is to check safety and how the drug moves through the body, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ASY202 (dihydroergotamine dry powder for inhalation)
- What this could lead to
- If safe and effective, this could point toward a new inhaled treatment to ease asthma symptoms.
- What could go wrong
- This is a very early Phase 1 safety trial with only 40 people, so it may not show clear benefit or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY IN ASTHMA PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
CenExel- Anaheim Clinical trials LLC
RECRUITINGAnaheim, California, 92801, United States
-
Sun City Clinical Research
RECRUITINGGlendale, Arizona, 85304, United States
-
Worldwide Clinical Trials- Early Phase Research Unit
RECRUITINGSan Antonio, Texas, 78217, United States